1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Inventiva S.A.

Inventiva S.A.

IVA.PA
Inventiva S.A.undefined flagEuronext Paris
3.29
EUR
-0.13
- -
456.82MMarket Cap
Inventiva S.A.
IVA.PA
(Euronext Paris)

Recent

price

3.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.31
0.33
0.49
0.6
0.31
0.16
0.3
0.01
0.11
0.29
0.39
0.15
0.02
Revenue per Share
-0.71
-0.75
-0.88
-0.45
-1.23
-1.61
-1.28
-0.99
-1.27
-1.31
-2.43
-3.08
-1.9
Basic EPS, GAAP
-1.79
-1.6
-1.49
-0.96
-1.12
-1.69
-1.21
-0.91
-1.23
-1.1
-1.81
-1.44
-0.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.7
-0.74
-0.87
-0.46
-1.22
-1.6
-1.27
-0.98
-1.26
-1.3
-2.42
-3.07
-1.89
Book Value per Share
5.68
4.92
4.03
2.12
3.87
2.92
1.71
3.26
2.25
1.08
-0.72
-1.78
-0.15
Tangible Book Value per Share
10
10
10
16
16
21
24
34
39
41
45
60
187
Basic Weighted Avg Shares
3
3
5
9
5
3
7
- -
4
12
17
9
4
Sales/Revenue/Turnover
-406.81
-410.22
-305.14
-127.56
-462.56
-958.68
-417.48
-7,136.02
-1,220.17
-466.84
-587.43
-1,021.84
-2,964.15
Operating Margin (%)
1
1
1
2
1
1
2
2
-1
2
3
5
3
Depreciation Expense
-7
-7
-9
-7
-19
-33
-30
-34
-50
-54
-110
-184
-354
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-232.82
-228.26
-181
-74.59
-397.81
-1,032.66
-431.81
-9,037.37
-1,183.48
-445.64
-631.84
-2,002.74
-7,899.58
Profit Margin (%)
11
16
21
32
58
57
35
119
93
76
-2
-9
167
Working Capital
- -
- -
1
- -
- -
- -
- -
10
9
29
32
48
28
LT Debt
59
52
43
35
62
62
41
111
89
45
-32
-107
-29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.32%
-15.93%
-73.26%
Free Cash Flow
26.41%
31.58%
21.88%
Net Income, GAAP
54.6%
63.9%
92.24%
Sales/Revenue/Turnover
119.81%
232.54%
-51.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17
2024
- -
- -
- -
- -
9
2025
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.43
2024
- -
- -
- -
- -
-3.08
2025
- -
- -
- -
- -
-1.9

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Medigen Vaccine Biologics Corp. (6547.TWO)
Polynovo Limited (CALZF)
Adaptimmune Therapeutics plc (ADAP)
BB Biotech AG (BBZA.DE)
Matinas BioPharma Holdings, Inc. (MTNB)
Aclaris Therapeutics, Inc. (0H8T.L)
Business
Inventiva S.A. (Euronext Paris: IVA; Nasdaq: IVA) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology; its lead product candidate, lanifibranor, a pan-PPAR agonist, advances in the phase 3 NATiV3 trial for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), demonstrating efficacy in resolving NASH without worsening fibrosis, improving fibrosis without worsening NASH, and achieving composite endpoints in prior phase 2b studies; the second clinical asset, odiparcil, targets mucopolysaccharidoses (MPS) by modifying glycosaminoglycan synthesis to promote urinary excretion; earlier-stage programs include preclinical efforts in TGF-beta for idiopathic pulmonary fibrosis, Hippo signaling pathway modulation, and oncology indications such as multiple myeloma and lung cancer. Founded in 2011 and headquartered at 50 rue de Dijon in Daix, France, the company leverages a proprietary discovery engine with a library of over 240,000 compounds, expertise in nuclear receptors, transcription factors, and epigenetic modulation, and partnerships including collaborations with AbbVie, Boehringer Ingelheim, Sino Biopharm, and Hepalys Pharma. Recent developments include the October 2025 launch of a $100 million at-the-market (ATM) equity offering program through Piper Sandler to fund lanifibranor development and operations, a November 2025 announcement of a $125 million public offering of American Depositary Shares (ADSs) representing new ordinary shares, and a strategic pipeline prioritization focusing clinical resources on lanifibranor while suspending odiparcil advancement and reviewing options for its future.